ROSGQ (Rosetta Genomics) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Rosetta Genomics 5-Year Yield-on-Cost %?

Rosetta Genomics ROSGQ 5-Year Yield-on-Cost % is 0.00 as of Jul. 13, 2026.

Rosetta Genomics's yield on cost for the quarter that ended in Jun. 2017 was 0.00.


The historical rank and industry rank for Rosetta Genomics's 5-Year Yield-on-Cost % or its related term are showing as below:



ROSGQ's 5-Year Yield-on-Cost % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.44
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Rosetta Genomics  (OTCPK:ROSGQ) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Rosetta Genomics 5-Year Yield-on-Cost % Related Terms

ROSGQ vs TEAR, IDTA, ABMC: 5-Year Yield-on-Cost % Comparison

For the Diagnostics & Research subindustry, Rosetta Genomics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rosetta Genomics 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's 5-Year Yield-on-Cost % falls into.


Rosetta Genomics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Rosetta Genomics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Rosetta Genomics (ROSGQ) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 13, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Rosetta Genomics and its competitors.
Is Rosetta Genomics' 5-Year Yield-on-Cost % too high?
Rosetta Genomics' current 5-Year Yield-on-Cost % is 0.00.
How does Rosetta Genomics' 5-Year Yield-on-Cost % compare to TEAR and IDTA?
Rosetta Genomics' 5-Year Yield-on-Cost % of 0.00 can be compared against companies in the Medical Diagnostics & Research industry. The industry median 5-Year Yield-on-Cost % is 2.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.44, based on 65 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Rosetta Genomics and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rosetta Genomics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rosetta Genomics Business Description

Address 10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.